LOGIN  |  REGISTER
Cue Biopharma

Aurora Spine Announces Participation at the North American Spine Society Annual Meeting

September 24, 2024 | Last Trade: C$0.31 0.02 5.08

CARLSBAD, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a leader in the development of groundbreaking medical devices for spinal surgery, today announced its participation at the 2024 North American Spine Society ("NASS") Annual Meeting. The event will take place from September 25-28, 2024, at McCormick Place, West Building, in Chicago, Illinois. Aurora Spine will be exhibiting at Booth #4510.

The North American Spine Society is a global multidisciplinary medical society that utilizes education, research, and advocacy to foster the highest quality, ethical, and evidence-based spine care. NASS gathers spine professionals from around the world, offering a unique platform for Aurora to showcase its latest innovations.

At this year’s event, the Company will feature its SiLO™ TFX SI Fusion System for sacroiliac joint fusion surgery and the DEXA-C cervical interbody cage system, powered by Aurora’s patented DEXA™ Technology. This technology offers patient-matched implants designed to align with individual bone density and T-Score, ushering in a new era of personalized spinal care. Aurora will also highlight the new Hydra™ and OSTEO-ONYX™ lumbar fusion systems, promoting Rough Surface Technology (RST), and its ZIP-51® Interlaminar Fusion System, which enables minimally invasive L5/S1 fusion without screws, improving procedural efficiency and patient recovery.

“We are excited to attend NASS 2024 and showcase the cutting-edge products we've developed,” said Trent Northcutt, President and CEO of Aurora Spine. "We’ve brought technologies to market that are transforming spinal surgery, and we can’t wait to share them with the industry."

Laszlo Garamszegi, Chief Technology Officer, added: "We’re particularly excited about the DEXA-C implant line, the world’s first patient-matched interbody implant system. It’s a true game-changer for spine surgeons and their patients."

“It is an honor to collaborate with thought-leading spine surgeons from around the world. It is with their guidance and support that we have brought life-changing technology to patients in need,” said Matthew Goldstone, Chief Commercial Officer.

Visit Aurora Spine at Booth #4510 to witness live demonstrations and engage with the Aurora team on how these innovations reshape spinal surgery.

About Aurora Spine

Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at www.aurora-spine.com or www.aurorapaincare.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.

Contact:

Aurora Spine Corporation

Trent Northcutt
President and Chief Executive Officer
(760) 424-2004

Chad Clouse
Chief Financial Officer
(760) 424-2004
www.aurora-spine.com

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB